Arcturus Therapeutics, Inc.

Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development, and commercialization of therapeutics for rare diseases and vaccines. Arcturus has a number of mRNA medicine development programs that leverage our proprietary LUNAR® delivery system and mRNA design and production capabilities.

We are committed to developing safe and effective therapies and vaccines, obtaining regulatory
approval, and providing our therapies and vaccines as quickly as possible to patients who are most likely
to benefit. At this point in the clinical development of our investigational products, participation in a
controlled clinical trial of an investigational Arcturus product is the best way for patients to access our
investigational products.

Our goals are to conduct research and development efforts with patient safety and efficacy at the forefront and to obtain regulatory approval for our investigational products so that they can be available to patients as quickly as possible. We encourage all individuals who think they may benefit from Arcturus’ investigational products to speak to their physicians about the possibility of enrolling in a clinical trial to support the development of promising new products. Treating physicians, patients, and/or caregivers can learn more about our investigational products in ongoing clinical trials, including study contacts to obtain more specific information, by visiting www.clinicaltrials.gov and searching for “Arcturus Therapeutics, Inc.” in the Other Terms search field.

Currently, we do not provide expanded access to our investigational products and do not accept expanded access requests. Expanded Access, also known as Compassionate Use, is an alternative process for the clinical use of an investigational product that has not yet been approved by the U.S. Food and Drug Administration (FDA) to treat, diagnose, or prevent a serious or immediately life-threatening disease or condition.

We will re-evaluate this policy periodically and may revise it at any time. If you have any questions about the Arcturus Therapeutics Expanded Access Policy, please contact us at EAP@arcturusrx.com. Arcturus expects to acknowledge receipt of any questions within five business days of receipt. Please do not send any personal or private health information to this email address.